Bio-Techne Corporation (TECH)
undefined
undefined%
At close: undefined
75.69
0.13%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.

The company operates through two segments, Protein Sciences, and Diagnostics and Genomics.

The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.

The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.

It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands.

The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.

Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corporation
Bio-Techne Corporation logo
Country United States
IPO Date Feb 9, 1989
Industry Biotechnology
Sector Healthcare
Employees 3,100
CEO Kim Kelderman

Contact Details

Address:
614 McKinley Place N.E.
Minneapolis, Minnesota
United States
Website https://www.bio-techne.com

Stock Details

Ticker Symbol TECH
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000842023
CUSIP Number 09073M104
ISIN Number US09073M1045
Employer ID 41-1427402
SIC Code 2836

Key Executives

Name Position
Kim Kelderman Chief Executive Officer, President & Director
Dr. Gary J. Latham Ph.D. Vice President & Chief Technology Officer
James T. Hippel CPA Executive Vice President of Finance & Chief Financial Officer
Cheryl Bethune Senior Vice President & Chief Human Resources Officer
David Clair C.F.A. Senior Director of Investor Relations & Corporate Development
Dr. Matthew F. McManus M.D., MBA, Ph.D. President of Diagnostics & Genomics
Gerry Andros Vice President of Sales and Marketing
Martin Wirtz Senior Vice President of Strategy & Corporate Development
Shane Bohnen Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer
William A. Geist President of Protein Sciences Segment

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 08, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 05, 2024 4 Filing
Nov 05, 2024 4 Filing
Nov 05, 2024 4 Filing
Nov 05, 2024 8-K Current Report
Nov 05, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Oct 28, 2024 4 Filing
Oct 28, 2024 4 Filing